HK1059290A1 - Isolating cells expressing secreted proteins - Google Patents

Isolating cells expressing secreted proteins

Info

Publication number
HK1059290A1
HK1059290A1 HK04101951A HK04101951A HK1059290A1 HK 1059290 A1 HK1059290 A1 HK 1059290A1 HK 04101951 A HK04101951 A HK 04101951A HK 04101951 A HK04101951 A HK 04101951A HK 1059290 A1 HK1059290 A1 HK 1059290A1
Authority
HK
Hong Kong
Prior art keywords
poi
isolating cells
cells expressing
secreted proteins
expressing secreted
Prior art date
Application number
HK04101951A
Other languages
English (en)
Inventor
James P Fandl
Neil Stahl
Gang Chen
George D Yancopoulos
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of HK1059290A1 publication Critical patent/HK1059290A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B30/00—Methods of screening libraries
    • C40B30/04—Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1051—Gene trapping, e.g. exon-, intron-, IRES-, signal sequence-trap cloning, trap vectors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Food Science & Technology (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
HK04101951A 2001-01-16 2004-03-17 Isolating cells expressing secreted proteins HK1059290A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26199901P 2001-01-16 2001-01-16
PCT/US2002/001208 WO2002057423A2 (en) 2001-01-16 2002-01-16 Isolating cells expressing secreted proteins

Publications (1)

Publication Number Publication Date
HK1059290A1 true HK1059290A1 (en) 2004-06-25

Family

ID=22995765

Family Applications (1)

Application Number Title Priority Date Filing Date
HK04101951A HK1059290A1 (en) 2001-01-16 2004-03-17 Isolating cells expressing secreted proteins

Country Status (10)

Country Link
US (3) US6919183B2 (xx)
EP (1) EP1392859B1 (xx)
JP (1) JP4323167B2 (xx)
AT (1) ATE325865T1 (xx)
AU (1) AU2002245272B2 (xx)
CA (1) CA2434802C (xx)
DE (1) DE60211329T2 (xx)
HK (1) HK1059290A1 (xx)
IL (2) IL156910A0 (xx)
WO (1) WO2002057423A2 (xx)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090137416A1 (en) 2001-01-16 2009-05-28 Regeneron Pharmaceuticals, Inc. Isolating Cells Expressing Secreted Proteins
JP4323167B2 (ja) * 2001-01-16 2009-09-02 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 分泌タンパク質を発現する細胞の単離
GB0118337D0 (en) * 2001-07-27 2001-09-19 Lonza Biologics Plc Method for selecting antibody expressing cells
JP2005526517A (ja) * 2002-05-22 2005-09-08 バイオジェン・アイデック・エムエイ・インコーポレイテッド 分泌性ポリペプチドの検出
US20040067532A1 (en) * 2002-08-12 2004-04-08 Genetastix Corporation High throughput generation and affinity maturation of humanized antibody
EP1658498A1 (en) 2003-08-20 2006-05-24 Celltech R & D Limited Methods for obtaining antibodies
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
TW200808739A (en) 2006-04-06 2008-02-16 Novartis Vaccines & Diagnostic Quinazolines for PDK1 inhibition
CN101512337A (zh) 2006-05-04 2009-08-19 阿布马克西斯公司 跨物种与多物种展示系统
CA2651478C (en) 2006-05-17 2015-02-03 Josef Endl Polypeptide producing cells
CA2671264C (en) 2006-11-30 2015-11-24 Research Development Foundation Improved immunoglobulin libraries
WO2008103474A1 (en) * 2007-02-20 2008-08-28 Anaptysbio, Inc. Methods of generating libraries and uses thereof
EP2137308B1 (en) * 2007-03-26 2016-08-03 Agenus Inc. Cell surface display, screening and production of proteins of interest
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
MX344415B (es) 2007-09-14 2016-12-15 Adimab Inc Bancos de anticuerpos sinteticos, designados racionalmente y usos para los mismos.
US8637435B2 (en) * 2007-11-16 2014-01-28 Merck Sharp & Dohme Corp. Eukaryotic cell display systems
CA2710122A1 (en) 2007-12-20 2009-07-02 Novartis Ag Thiazole derivatives used as pi 3 kinase inhibitors
WO2009103753A1 (en) * 2008-02-20 2009-08-27 Ablynx Nv Methods for identifying and/or sorting cells by secreted molecule and kits for performing such methods
CA2715212A1 (en) * 2008-03-03 2009-09-11 Glycofi, Inc. Surface display of recombinant proteins in lower eukaryotes
US8067339B2 (en) 2008-07-09 2011-11-29 Merck Sharp & Dohme Corp. Surface display of whole antibodies in eukaryotes
EP2573122A3 (en) * 2008-12-04 2013-07-10 Korea Research Institute of Bioscience and Biotechnology Screening of abundantly secreted proteins and their use as fusion partners for the production of recombinant proteins
PL3279326T3 (pl) 2009-06-02 2021-03-08 Regeneron Pharmaceuticals, Inc. Komórki z deficytem fukozylacji
US8293753B2 (en) 2009-07-02 2012-10-23 Novartis Ag Substituted 2-carboxamide cycloamino ureas
US8278873B2 (en) * 2009-09-10 2012-10-02 Syntheon, Llc Surgical sterilizer with integrated battery charging device
KR20120117931A (ko) 2010-02-12 2012-10-24 온코메드 파마슈티칼스, 인크. 폴리펩타이드를 발현하는 세포를 확인 및 분리하는 방법
EP2390661B1 (en) 2010-05-02 2015-06-24 Miltenyi Biotec GmbH An anchoring/capturing means for selecting or analyzing a CHO cell according to a product secreted by the CHO cell
WO2011159847A2 (en) 2010-06-15 2011-12-22 The Regents Of The University Of California Receptor tyrosine kinase-like orphan receptor 1 (ror1) single chain fv antibody fragment conjugates and methods of use thereof
KR102318383B1 (ko) 2010-07-16 2021-10-27 아디맵 엘엘씨 항체 라이브러리
AR082418A1 (es) 2010-08-02 2012-12-05 Novartis Ag Formas cristalinas de 1-(4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il)-amida de 2-amida del acido (s)-pirrolidin-1,2-dicarboxilico
KR101291241B1 (ko) 2010-11-04 2013-08-01 한국생명공학연구원 효모에서 인체 상피세포 성장인자를 대량 생산하는 방법
IL210093A0 (en) * 2010-12-19 2011-06-30 David Helman Membrane bound reporter molecules and their use in cell sorting
EP2658971A1 (en) 2010-12-28 2013-11-06 XOMA Technology Ltd. Cell surface display using pdz domains
ES2634098T3 (es) 2011-01-14 2017-09-26 The Regents Of The University Of California Anticuerpos terapéuticos contra la proteína ROR-1 y procedimientos para el uso de los mismos.
PL2670753T3 (pl) 2011-01-31 2017-05-31 Novartis Ag Nowe pochodne heterocykliczne
CN102680679B (zh) * 2011-03-15 2014-08-27 中国科学院上海生命科学研究院 检测单细胞特异性抗体分泌的细胞微孔芯片及其制备方法
MX340452B (es) 2011-10-28 2016-07-08 Novartis Ag Novedosos derivados de purina y su uso en el tratamiento de enfermedades.
WO2013169609A1 (en) 2012-05-11 2013-11-14 Merck Sharp & Dohme Corp. Surface anchored light chain bait antibody display system
WO2013173283A1 (en) 2012-05-16 2013-11-21 Novartis Ag Dosage regimen for a pi-3 kinase inhibitor
TW201823460A (zh) 2012-05-29 2018-07-01 美商再生元醫藥公司 生產細胞株增強子
US9758591B2 (en) 2012-08-24 2017-09-12 The Regents Of The University Of California Antibodies and vaccines for use in treating ROR1 cancers and inhibiting metastasis
TWI745610B (zh) * 2012-11-14 2021-11-11 美商再生元醫藥公司 重組細胞表面捕捉蛋白質
TWI635098B (zh) 2013-02-01 2018-09-11 再生元醫藥公司 含嵌合恆定區之抗體
EP2970415B1 (en) 2013-03-14 2018-12-19 Regeneron Pharmaceuticals, Inc. Apelin fusion proteins and uses thereof
AR095196A1 (es) 2013-03-15 2015-09-30 Regeneron Pharma Medio de cultivo celular libre de suero
GB201316644D0 (en) 2013-09-19 2013-11-06 Kymab Ltd Expression vector production & High-Throughput cell screening
HUE039551T2 (hu) 2013-10-11 2019-01-28 Regeneron Pharma Metabolikusan optimalizált sejttenyészet
CA2930359C (en) 2013-12-06 2022-03-01 Novartis Ag Dosage regimen for an alpha-isoform selective phosphatidylinositol 3-kinase inhibitor
AR102333A1 (es) 2014-08-19 2017-02-22 Regeneron Pharma Selectividad eficiente de proteínas recombinadas
TW202340452A (zh) 2015-08-04 2023-10-16 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法
WO2017077445A1 (en) 2015-11-02 2017-05-11 Novartis Ag Dosage regimen for a phosphatidylinositol 3-kinase inhibitor
WO2017132701A1 (en) * 2016-01-31 2017-08-03 Shuang Zhang Method for screening antibodies
US11053288B2 (en) * 2016-02-04 2021-07-06 Trianni, Inc. Enhanced production of immunoglobulins
WO2017203046A1 (en) 2016-05-26 2017-11-30 University College Cork - National University Of Ireland, Cork Methods for increasing proliferation of mammalian cells
WO2017203051A1 (en) 2016-05-26 2017-11-30 University College Cork - National University Of Ireland, Cork An engineered gram positive bacterium
MY196869A (en) 2016-06-27 2023-05-05 Univ California Cancer treatment combinations
WO2018041740A1 (en) 2016-09-01 2018-03-08 Bayer Pharma Aktiengesellschaft Non-covalent display system using fimgt/dsf
WO2018060833A1 (en) 2016-09-27 2018-04-05 Novartis Ag Dosage regimen for alpha-isoform selective phosphatidylinositol 3-kinase inhibitor alpelisib
JP6818134B2 (ja) 2016-09-29 2021-01-20 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ポリペプチド産生細胞を選択するための改善された方法
GB201703418D0 (en) 2017-03-03 2017-04-19 Ge Healthcare Bio Sciences Ab Method for cell line development
GB201704115D0 (en) * 2017-03-15 2017-04-26 Oxford Genetics Ltd Method of selecting for antibodies
US11946074B2 (en) 2017-03-24 2024-04-02 Lankenau Institute For Medical Research Methods and compositions for inducible extracellular membrane capture of monoclonal immunoglobulins secreted by hybridomas
EP3673044A1 (en) 2017-08-25 2020-07-01 University College Cork-National University of Ireland, Cork Bifidobacterium longum for treating obesity and weight management
EP3713587B1 (en) 2017-11-24 2024-03-27 University College Cork-National University of Ireland, Cork A composition comprising a cohort of bacteria
EP3604507A1 (en) 2018-07-30 2020-02-05 University College Cork-National University of Ireland, Cork An omega-transaminase enzyme
CA3154132A1 (en) * 2018-09-17 2020-03-26 South Australian Health And Medical Research Institute Limited Methods for producing proteins
CA3133361A1 (en) * 2019-04-03 2020-10-08 Regeneron Pharmaceuticals, Inc. Methods and compositions for insertion of antibody coding sequences into a safe harbor locus
EP4017518A1 (en) 2019-08-20 2022-06-29 Nuritas Limited Peptides for treating muscle atrophy
EP3783012A1 (en) 2019-08-20 2021-02-24 Nuritas Limited An antimicrobial peptide
WO2021078912A1 (en) 2019-10-22 2021-04-29 Nuritas Limited Treatment of non-alcoholic fatty liver disease
JPWO2022190733A1 (xx) * 2021-03-10 2022-09-15
EP4070670A1 (en) 2021-04-08 2022-10-12 University College Cork-National University of Ireland Cork Lacticaseibacillus paracasei em025-11 and uses thereof
AU2022259568A1 (en) 2021-04-14 2023-11-09 University College Cork - National University Of Ireland, Cork Psg1 for use in the treatment of osteoarthritis
CN117651564A (zh) 2021-04-14 2024-03-05 爱尔兰国立科克大学 脑血管事件和神经系统疾病的治疗
US20230110811A1 (en) 2021-10-07 2023-04-13 Regeneron Pharmaceuticals, Inc. pH METER CALIBRATION AND CORRECTION
AU2022360838A1 (en) 2021-10-07 2024-03-28 Regeneron Pharmaceuticals, Inc. Systems and methods of ph modeling and control
WO2023167863A1 (en) 2022-03-02 2023-09-07 Regeneron Pharmaceuticals, Inc. Manufacturing process for high titer antibody
WO2024078729A1 (en) 2022-10-14 2024-04-18 University College Cork - National University Of Ireland, Cork Placenta expressed proteins for use in the treatment of tendon injury
CN118006552A (zh) * 2024-04-09 2024-05-10 暨南大学 一种抗原特异性浆细胞的筛选方法及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1324040A3 (en) * 1992-10-21 2007-06-20 MILTENYI, Stefan Direct selection of cells by secretion product
US6287784B1 (en) * 1993-11-23 2001-09-11 Genentech, Inc. Kinase receptor activation assay
BRPI9715219B8 (pt) * 1996-02-09 2015-07-07 Abbvie Biotechnology Ltd Vetor recombinante de expressão, e célula hospedeira procariótica.
WO1999058977A1 (en) 1998-05-11 1999-11-18 Miltenyi Biotec Gmbh Method of direct selection of antigen-specific t cells
TR200504220T2 (tr) * 1998-12-17 2007-04-24 Biogen Idec Ma Inc. Aktif limfotoksin-beta reseptör imunoglobülin şimeAktif limfotoksin-beta reseptör imunoglobülin şimerik proteinlerinin yüksek düzey ifadesi ve saflaştrik proteinlerinin yüksek düzey ifadesi ve saflaştırılması için bir yöntem.ırılması için bir yöntem.
DE19900635A1 (de) * 1999-01-11 2000-07-13 Deutsches Krebsforsch Selektion von monoklonalen Antikörpern
JP4323167B2 (ja) * 2001-01-16 2009-09-02 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 分泌タンパク質を発現する細胞の単離

Also Published As

Publication number Publication date
AU2002245272B2 (en) 2006-06-29
WO2002057423A3 (en) 2003-12-18
US20060234311A1 (en) 2006-10-19
DE60211329D1 (de) 2006-06-14
US20050186623A1 (en) 2005-08-25
WO2002057423A2 (en) 2002-07-25
EP1392859A4 (en) 2004-11-24
ATE325865T1 (de) 2006-06-15
CA2434802C (en) 2013-05-28
US7435553B2 (en) 2008-10-14
US20020168702A1 (en) 2002-11-14
EP1392859A2 (en) 2004-03-03
EP1392859B1 (en) 2006-05-10
IL156910A (en) 2009-08-03
JP2004520037A (ja) 2004-07-08
DE60211329T2 (de) 2007-05-24
IL156910A0 (en) 2004-02-08
US6919183B2 (en) 2005-07-19
CA2434802A1 (en) 2002-07-25
JP4323167B2 (ja) 2009-09-02

Similar Documents

Publication Publication Date Title
HK1059290A1 (en) Isolating cells expressing secreted proteins
WO2002034906A3 (de) Verfahren zur exposition von peptiden und polypeptiden auf der zelloberfläche von bakterien
WO2003068947A8 (en) Assay electrodes having immobilized lipid/protein layers and methods of making and using the same
WO2002079490A3 (en) Bio-barcodes based on oligonucleotide-modified particles
ATE393228T1 (de) Fusionsproteine und deren verwendung zur messung von protease-aktivität
WO2002004523A3 (en) Artificial antibody polypeptides
EP1499885A4 (en) NOVEL FUSION PROTEINS AND ANALYSIS FOR THE DETECTION OF MOLECULAR BINDERS
DK1410023T3 (da) Fremgangsmåder til anvendelse af 06-alkylguanin-DNA-alkyltransferaser
WO2003087129A3 (en) Immunogenic peptides, and method of identifying same
WO2006107813A3 (en) Site specific incorporation of phosphoserine into polypeptides using phosphoseryl-trna synthetase
BR9912455A (pt) ácidos nucléicos codificadores de proteìnas envolvidas em transdução sensória
WO1999009179A3 (en) Antigen constructs useful in the detection and differentiation of antibodies to hiv
WO2006127822A3 (en) Scytovirin domain 1 related polypeptides
WO2003018797A3 (en) Method and device for integrated protein expression, purification and detection
WO2003016904A3 (en) Peptide sequence tags and method of using same
WO2002064747A3 (en) Fusion proteins based upon somatostatin receptors
WO2003020005A3 (en) Lp mammalian proteins; related reagents
WO2003062444A3 (en) Array systems and methods
WO2003033650A3 (en) Recombinant renilla reniformis system for bioluminescence resonance energy transfer
HUP0101987A2 (hu) Antibiotikus hatású proteinek és peptidek indukciója LAIT/sCD14-proteinnel
WO2005001099A3 (en) Protein expression system
ATE307142T1 (de) Zweifarbiges fluorimetrisches proteaseassay
WO2002042458A3 (en) G protein coupled receptors
WO2002074906A3 (en) Lp mammalian proteins; related reagents
ATE348190T1 (de) Verfahren zum nachweis von protein- proteininteraktionen in membranen

Legal Events

Date Code Title Description
PE Patent expired

Effective date: 20220115